Level C· Early human research exploring benefitsProspective StudyPubMed

[Comparative analysis of cell populations with a phenotype similar to that of mesenchymal stem cells derived from subcutaneous fat].

Tepliashin AS., Chupikova NI., Korzhikova SV., Sharifullina SZ., Rostovskaia MS., Topchiashvili ZA.

Prospective Study on Face & Skin, published in Tsitologiia (2005) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Tsitologiia (2005)
Country
Russia (Federation)
Reported sample size
—
Source database
PubMed
PMID
16706228

Abstract (original English)

Two cell populations with a phenotype similar to that of mesenchymal stem cells (MSC) with different characteristics for expression of surface antigene CD34 were derived from subcutaneous fat. CD34-positive cells were derived from subcutaneous fat of the inferior eyelid obtained during transconjuctival blepharoplasty. CD34-negative cells were derived from adipose tissue obtained during lipoaspiration from the same patients. These cells displayed common characteristics for morphology and expression of basic markers characterizing them as mesenchymal stem cells. On being induced for differentiation, these two cell populations were able to differentiate to cells of adipose (adipocytes), bone (osteoblastes, osteocytes), cartilage (chondroblasts, chondrocytes), and nervous (neurons, astrocytes and oligodendrocytes) tissues.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Antigens, CD34BlepharoplastyCell DifferentiationCells, CulturedEyelidsHumansLipectomyMesenchymal Stem CellsOrgan SpecificitySubcutaneous Fat

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research